82 related articles for article (PubMed ID: 25537090)
1. Survinin expression in patients with breast cancer during chemotherapy.
Marsicano SR; Kuniyoshi RK; Gehrke FS; Alves BC; Azzalis LA; Fonseca FL
Tumour Biol; 2015 May; 36(5):3441-5. PubMed ID: 25537090
[TBL] [Abstract][Full Text] [Related]
2. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
Yie SM; Luo B; Ye NY; Xie K; Ye SR
Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
[TBL] [Abstract][Full Text] [Related]
3. Axillary lymph node metastasis: CA-15-3 and carcinoembryonic antigen concentrations in fine-needle aspirates for preoperative diagnosis in patients with breast cancer.
Kim MJ; Park BW; Lim JB; Kim HS; Kwak JY; Kim SJ; Park SH; Sohn YM; Moon HJ; Kim EK
Radiology; 2010 Mar; 254(3):691-7. PubMed ID: 20123899
[TBL] [Abstract][Full Text] [Related]
4. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
5. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
6. The relationship between circulating carcinoembryonic antigen (CEA) levels and parameters of primary tumor and metastases in breast cancer patients.
Mujagić Z; Mujagic H; Prnjavorac B
Med Arh; 2004; 58(1):23-6. PubMed ID: 15017899
[TBL] [Abstract][Full Text] [Related]
7. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
8. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.
Stathopoulou A; Vlachonikolis I; Mavroudis D; Perraki M; Kouroussis Ch; Apostolaki S; Malamos N; Kakolyris S; Kotsakis A; Xenidis N; Reppa D; Georgoulias V
J Clin Oncol; 2002 Aug; 20(16):3404-12. PubMed ID: 12177100
[TBL] [Abstract][Full Text] [Related]
9. [mRNA expression of CK19 and CEA in peripheral blood of patients with breast cancer detected by real-time quantitative PCR].
Zheng HY; Chen Q; Ye YB; Huang WW
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(32):2267-70. PubMed ID: 19087676
[TBL] [Abstract][Full Text] [Related]
10. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
11. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
[TBL] [Abstract][Full Text] [Related]
12. [Tumor markers of breast cancer].
Sławicki S; Mroczko B; Szmitkowski M
Postepy Hig Med Dosw (Online); 2004 Jul; 58():292-300. PubMed ID: 15280799
[TBL] [Abstract][Full Text] [Related]
13. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of Smac and survivin expression in breast cancer patients treated with anthracycline‑based neoadjuvant chemotherapy.
Zhao YC; Wang Y; Ni XJ; Li Y; Wang XM; Zhu YY; Luo CY
Mol Med Rep; 2014 Feb; 9(2):614-20. PubMed ID: 24317109
[TBL] [Abstract][Full Text] [Related]
15. Ratio of proliferation markers and HSP90 gene expression as a predictor of pathological complete response in breast cancer neoadjuvant chemotherapy.
Jarzab M; Kowal M; Bal W; Oczko-Wojciechowska M; Rembak-Szynkiewicz J; Kowalska M; Stobiecka E; Chmielik E; Tyszkiewicz T; Kaszuba M; Nowicka E; Lange B; Czarniecka A; Krajewska J; Dyla A; Dobrut M; Lange D; Jarzab B; Bobek-Billewicz B; Tarnawski R
Folia Histochem Cytobiol; 2016; 54(4):202-209. PubMed ID: 28051275
[TBL] [Abstract][Full Text] [Related]
16. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin.
Stoetzer OJ; Fersching DM; Salat C; Steinkohl O; Gabka CJ; Hamann U; Braun M; Feller AM; Heinemann V; Siegele B; Nagel D; Holdenrieder S
Cancer Lett; 2013 Aug; 336(1):140-8. PubMed ID: 23612068
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers in fine-needle aspiration washout for cervical lymphadenopathy in patients with known malignancy: preliminary study.
Suh YJ; Kim MJ; Kim J; Yoon JH; Moon HJ; Kim EK
AJR Am J Roentgenol; 2011 Oct; 197(4):W730-6. PubMed ID: 21940546
[TBL] [Abstract][Full Text] [Related]
18. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients.
Bostick PJ; Chatterjee S; Chi DD; Huynh KT; Giuliano AE; Cote R; Hoon DS
J Clin Oncol; 1998 Aug; 16(8):2632-40. PubMed ID: 9704713
[TBL] [Abstract][Full Text] [Related]
19. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
[TBL] [Abstract][Full Text] [Related]
20. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
